Cancer treatment today largely relies on single-asset, single-indication approaches with conventional drug development pipelines that are slow, costly, and reactive. Patient stratification is limited, data and tools remain fragmented, and there is no integrated AI-plus-therapeutics ecosystem to enable predictive, personalized, and preventive oncology care. NK1R overexpression has been identified across multiple solid tumors and hematological malignancies, yet no targeted NK1R antagonist has been advanced into clinical oncology development.

LZ-167 is a repurposed NK1R antagonist with an established human safety profile, being developed as a precision oncology platform. It blocks NK1R signaling to inhibit tumor cell proliferation, angiogenesis, migration, and metastasis, while inducing apoptosis and restoring immune response. Broad antitumor activity has been demonstrated across more than 20 cancer models in vitro and in vivo. The full preclinical program (toxicology, PK, efficacy, mechanism of action, CMC and formulation) is complete. A pre-IND package is in preparation for FDA submission via the 505(b)(2) regulatory pathway, targeting a Phase I/IIa dose-escalation and expansion trial in advanced solid tumors. KeyZell pairs this therapeutic with an integrated AI-driven medicine approach and international translational infrastructure.